Barclays lowered the firm’s price target on OptimizeRx to $11 from $15 and keeps an Equal Weight rating on the shares. The post-Q2 selloff reflects a step back in the company’s still nascent track record more than concern over underlying earnings, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX: